CAJ | 학술논문

缺血性脑卒中发作后,一定时间内可以通过治疗减轻脑损伤的程度、促进机能恢复、改善长期预后，这个允许的时间称为治疗时间窗。它与缺血半暗带的转归密切相关，PAF受体拮抗剂、以TXA2为靶点的药物及药物联合应用等可以延缓或逆转缺血半暗带损伤，有助于延长时间窗。本文综述了脑缺血半暗带的发病机制及近5年来抗缺血性脑卒中治疗时间窗的药物研究进展，以期为临床用药提供可靠的理论依据。
결혈성뇌졸중발작후,일정시간내가이통과치료감경뇌손상적정도、촉진궤능회복、개선장기예후，저개윤허적시간칭위치료시간창。타여결혈반암대적전귀밀절상관，PAF수체길항제、이TXA2위파점적약물급약물연합응용등가이연완혹역전결혈반암대손상，유조우연장시간창。본문종술료뇌결혈반암대적발병궤제급근5년래항결혈성뇌졸중치료시간창적약물연구진전，이기위림상용약제공가고적이론의거。
After ischemic stroke, there is a period of time called therapeutic time window for reducing the degree of brain injury, promoting the function recovery and improving the long-term outcome. It is closely related to ischemic penumbra outcomes, besides, the application of PAF receptor antagonists, TXA2 targeting drugs or drug combinations can slow or reverse ischemic penumbra damages, which can extend the time window. This paper reviews the mechanism of ischemic penumbra and time window of anti-stroke drug treatment that have been researched for the past five years, which provides more chances for clinical medicine.